WuXi Biologics (Cayman) Inc. (WXIBF) Stock Price & Analysis
WuXi Biologics (Cayman) Inc. (WXIBF) closed at USD 6.45 on Wednesday, October 21, 2026, up 1.42% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 6.36; the Oct 21, 2026 session ranged USD 6.45–6.45 on volume of 4,000 shares. Market capitalization is $26.55B, with a 52-week range of USD 3.9–7.49 (PNK). Source: Nexqual, retrieved October 23, 2026 at 16:41 UTC.
Also available as compact Markdown for AI agents: nexqual.com/WXIBF.md
Key facts (WXIBF)
- Analysts: None.
- Total return with dividends: 1Y +18.7% vs S&P 500 +14.6%; 5Y -57.0% vs S&P 500 +77.3%.
- Next earnings: 2026-08-25, EPS estimate USD —, revenue estimate $0K.
Analysts (WXIBF)
Consensus None.
Total return (dividends reinvested) (WXIBF)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +18.7% | -57.0% |
| S&P 500 (SPY) | +14.6% | +77.3% |
| Per year | +18.7% | -15.6% |
| Volatility (annualized) | 56.0% | 76.8% |
| Max drawdown | -28.7% (Oct 2026→Oct 2026) | -91.3% (Oct 2021→Aug 2024) |
WXIBF analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends Dec 2026) | — | — | — | $25.69B | — |
| Next fiscal year (ends Dec 2027) | — | — | — | $30.71B | — |
Key Statistics (as of October 23, 2026 at 16:41 UTC)
| Price | USD 6.45 |
|---|---|
| Change | ▲ 1.42% (up) |
| Previous Close | USD 6.36 |
| Open | USD 6.45 |
| Day Range | USD 6.45 – 6.45 |
| 52-Week Range | USD 3.9 – 7.49 |
| Volume | 4,000 shares |
| Market Cap | $26.55B |
| Exchange | PNK |
Technical Analysis (WXIBF)
Nexqual's technical model rates WXIBF "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 16:41 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 31.9 (neutral) |
| vs SMA50 | Above (USD 6.35) |
| MACD | -0.03 (negative) |
Analyst Ratings (WXIBF)
Wall Street analysts rate WXIBF "None", per Nexqual as of October 23, 2026 at 16:41 UTC.
| Consensus Rating | None |
|---|
Earnings (WXIBF)
| Next Earnings Date | 2026-08-25 |
|---|
Source: Nexqual, October 23, 2026 at 16:41 UTC.
Financials & Fundamentals (WXIBF)
| Total Revenue | $23.62B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +18.40% |
| Gross Margin | +47.47% |
| Operating Margin | +31.63% |
| Profit Margin | +21.20% |
| ROE | +11.38% |
| Debt / Equity | 0.05 |
| Current Ratio | 3.32 |
| Total Cash | $13.03B |
| Total Debt | $2.73B |
Source: Nexqual, October 23, 2026 at 16:41 UTC.
Financial Health Score (WXIBF)
Nexqual rates WuXi Biologics (Cayman) Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 16:41 UTC.
| Growth | Strong — Revenue +17% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 47%, operating 32% (last 12 months) |
| Balance Sheet | Strong — CNY 13.0B cash vs CNY 2.73B debt, net cash position |
| Cash Flow | Solid — Operating cash flow CNY 8.82B (TTM) |
| Efficiency | Mixed — ROE 11%, ROA 7.6% |
Ownership (WXIBF)
| Insider Ownership | +7.93% |
|---|---|
| Institutional Ownership | +36.68% |
| Shares Outstanding | 4.12B |
| Float | 3.71B |
Source: Nexqual, October 23, 2026 at 16:41 UTC.
Leadership (WXIBF)
WuXi Biologics (Cayman) Inc. is led by Zhisheng Chen, CEO & Executive Director, per Nexqual as of October 23, 2026 at 16:41 UTC.
| CEO & Executive Director | Zhisheng Chen |
|---|---|
| Founder & Chairman | Ge Li |
| CTO, Chief Client Officer, EVP of Global Biologics Development Department & Executive Director | Xuejun Gu |
| CFO & Executive VP | Ming Tu |
| COO & Senior VP | Lihua Yu |
Major Backers & Investors (WXIBF)
Notable institutional backers of WuXi Biologics (Cayman) Inc. include American Century ETF Trust-Avantis Emerging Markets Equity ETF, J.P. Morgan Exch-Trd Fd. TRT-JPMorgan BetaBuilders Developed Asia Paci, Baird Funds Inc-Baird Chautauqua International Growth Fund, according to Nexqual as of October 23, 2026 at 16:41 UTC.
Active Investors
| Investor | Stake |
|---|---|
| American Century ETF Trust-Avantis Emerging Markets Equity ETF | 0.29% |
| J.P. Morgan Exch-Trd Fd. TRT-JPMorgan BetaBuilders Developed Asia Paci | 0.26% |
| Baird Funds Inc-Baird Chautauqua International Growth Fund | 0.21% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.75% |
| BlackRock | 1.4% |
Source: Nexqual, October 23, 2026 at 16:41 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ROIV | Roivant Sciences Ltd. | USD 36.98 | ▼ 1.26% |
| GMAB | Genmab A/S | USD 42.04 | ▲ 5.1% |
| INCY | Incyte Corporation | USD 115.94 | ▼ 0.85% |
| ALNY | Alnylam Pharmaceuticals, Inc. | USD 225.41 | ▼ 0.82% |
| BNTX | BioNTech SE | USD 88.7 | ▼ 1.09% |
| INSM | Insmed Incorporated | USD 94.24 | ▼ 0.86% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 16:41 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt